Clinical grade oral inhibitors of JAK1 and JAK2, such as fedratinib (SAR302503/TG101348) or ruxolitinib, which blocks phosphorylation of STAT1 and STAT3 [60] have been recently proposed for clinical evaluation for the treatment of ABC-DLBCL [60, 316, 317]. Here, STAT3 is linked to aneurysmal bone cyst.